Prev Close | 62.40 |
Day Low/High | 62.13 / 63.59 |
52 Wk Low/High | 56.56 / 85.97 |
Prev Close | 62.40 |
Day Low/High | 62.13 / 63.59 |
52 Wk Low/High | 56.56 / 85.97 |
Exchange | NASDAQ |
Shares Outstanding | 1253.53B |
Market Cap | 78.22B |
P/E Ratio | 63.67 |
Div & Yield | N.A. (N.A) |
Some tried-and-true indicators show what's really going on with the market.
M&A activity is in a serious upswing, and here are some names to watch.
Don't fight the trend of this stock.
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
Fear and doubt seem to have abandoned Wall Street. Dr. Hussman, while very much perma-bear, makes some good points in his weekly market commentary. See boldface. As does my pal Sir Mark Grant on CNBC's Squawk Box. I have reduced my large SPRD G...
Watch these five stocks very closely in the weeks ahead. You might be able to find a good place to jump out.
Static doesn't work in this industry. Pipelines work.
Market are still slightly down across the board as we approach the noon hour. Biotech is hanging in there well despite shellacking Gilead Sciences is taking after ratcheting down guidance. Helping the market is mid-cap concern Tesaro , which is cur...
Stocks trade mixed as energy shares rebound and financials stocks lag.
Jim Cramer explains the problem with Gilead's stock.
Markets are slightly down in the early going. Gilead Science GILD is off about 9% on dismal revenue guidance for 2017 and price target downward revisions at various analyst firms. If 2017 projections do not light a fire under company to use mergers ...
This is what you need to know before the opening bell.
I'm glad to be sitting in for Doug Kass on the Daily Diary over the next two days. There is plenty to talk about. Because we are the heart of earnings season, let's start with the quarterly results from two well-known large-cap concerns. It is going...
The rest of Gilead's house is in need of serious repair.
We are likely in a Trump-centric investment world in 2017. My theme that the president will make market volatility and uncertainty great again, continues. Consider the contrary, Part Deux. Mo' gold and I will accumulate under any weakness go...
We could see a healthy pullback and still remain bullish.
"The Dow hit 20,000 and I am proud of it ... Now we have to go up, up, up. It's gone up a lot since I won. We hit a number that has never been hit before. So, I am very honored." --President Donald Trump, ABC interview Wednesday night If the market ...
It is difficult to say at what level buyers may show up.
The market pushed back presumably after it digested the inaugural speech and absorbed the marches around the world. I don't believe the new president will be market and economy friendly. The reflation trade is in question today. And I remain b...
If you buy right, time and value should do most of the heavy lifting for you.
Deals already are popping up, and we'll soon have earnings reports from the industry giants.
Animal health and oncology deal activity is heating up in 2017.
At least, that's the case when it comes to a technical trade.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Watch out for these stocks as we start 2017.
Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.
Shares are dirt cheap as revenues and profits have grown.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
I love gold. Trade of the Week -- short Apple at $116.15. (The SoftBank investment is a non-event). Dwyerama is chillin' and I am re-establishing my ProShares UltraShort S&P500 ETF long -- back in a revolutionary mindset. As January goes......